IRON

IRON

USD

Disc Medicine Inc. Common Stock

$86.060+3.050 (3.674%)

Precio en Tiempo Real

Healthcare
Biotecnología
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$83.010

Máximo

$87.125

Mínimo

$83.010

Volumen

0.64M

Fundamentos de la Empresa

Capitalización de Mercado

3.2B

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

0.43M

Bolsa

NGM

Moneda

USD

Rango de 52 Semanas

Mínimo $30.82Actual $86.060Máximo $95.95

Noticias Relacionadas

GlobeNewswire

Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for

Ver más
Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
Analyst Upgrades

Stifel Reinstates Buy on Disc Medicine, Announces $125 Price Target

Stifel analyst Stephen Willey reinstates Disc Medicine with a Buy and announces $125 price target.

Ver más
Stifel Reinstates Buy on Disc Medicine, Announces $125 Price Target
GlobeNewswire

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for

Ver más
Disc Medicine to Participate in Upcoming Investor Conferences
Analyst Upgrades

Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $115

Morgan Stanley analyst Sean Laaman maintains Disc Medicine with a Overweight and raises the price target from $90 to $115.

Ver más
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $115

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.